Publication | Closed Access

CD7 targeted “off-the-shelf” CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies

Cell TherapyCancer ImmunosurveillanceMedicineImmunologyTumor ImmunityVivo ExpansionCd4 T Cell ResponsesCellular Immune ResponseImmunotherapyOncologyRadiation OncologyHigh Efficacy